护城河对比

The FY2025 20-F positions Nebius as 'one of the few global, at scale, multi-tenant clouds purpose built for AI,' but the same filing names its central dependency plainly: 'We currently rely on Nvidia for the GPU chips we use' — a purpose-built neocloud renting a supply the hyperscalers it competes with also control, which is a real but narrow position.

来源：sec.gov

The FY2025 10-K names Broadcom, Credo, Marvell, Microchip, Montage, Parade and Rambus as principal competitors who compete 'with respect to some, but not all' of the solutions — a defensible platform position inside a crowded, larger-capitalized field.

来源：sec.gov

The FY2025 10-K publishes the expiry schedule of its own protection. The Patents table dates the basic U.S. product patent on Eliquis ($7,961 million of 2025 revenue) to 2027, the Prevnar family's Prevnar 13 ($6,494 million for the family) to 2026, the Vyndaqel family ($6,380 million) to 2026 with a 2028 extension only pending, Ibrance ($4,122 million) to 2027, Xtandi ($2,194 million) to 2027 and Xeljanz ($1,087 million) to 2026 - against Total revenues of $62,579 million. The filing then states it anticipates 'a significant reduction of revenue from patent-based or regulatory exclusivity expiries in 2026 through 2030 as several of our in-line products experience these expirations, with the rate of the reduction of revenues from patent-based or regulatory exclusivity expiries expected to significantly accelerate over the next few years', and puts the 2026 instalment at $1.5 billion. A protection whose end dates the issuer tabulates product by product, and whose revenue effect it forecasts as accelerating, is being consumed on a clock it has already disclosed.

来源：sec.gov

The moat the filing describes is engineering: designs that 'optimize power and cooling efficiency, lower latency' plus 'a consistent track record of being one of the first-to-deploy the latest generation of NVIDIA GPU chips' — density and time-to-deploy at scale, not a switching lock.

来源：sec.gov

The COSMOS software suite is 'embedded in our connectivity products and integrated into our customers' systems,' and the Interop Lab validates compatibility 'early in their product development process and prior to large-scale deployments' — design-in before deployment is the lock.

来源：sec.gov

The filing locates the protection in the patent estate, not anywhere else. The Patents and Other Intellectual Property Rights section tabulates 'the patent rights we consider most significant in relation to our business as a whole, together with the year in which the basic product patent expires', and states that once protection is lost 'we typically lose market exclusivity on these products, and generic and biosimilar pharmaceutical manufacturers generally produce identical or highly similar products and sell them for a lower price.' The Competition section names patents as the thing rivals attack: 'several of our competitors operate without large R&D expenses and make a regular practice of challenging our product patents before their expiration', and 'Generic pharmaceutical manufacturers pose one of the biggest competitive challenges to our branded small molecule products because they can market a competing version of our product after the expiration or loss of our patent protection.' No network, switching cost or cost-curve advantage is claimed anywhere in the section.

来源：sec.gov

The 20-F's own claim is 'one of the FEW global, at scale' AI clouds — a differentiated challenger to the hyperscalers it names as the competitive field, not a claimed leader of it; the first-to-deploy record is a follower's speed advantage, not category leadership.

来源：sec.gov

Named by rivals as well as naming them: Credo's own 10-K lists Astera as its most direct PCIe-retimer competitor, and this filing names seven competitors against parts of the platform — a co-leadership contest, not a settled hierarchy.

来源：sec.gov

The 2026 Pharma 50 (Drug Discovery & Development, published 31 March 2026, ranking pharmaceutical revenue only) places Pfizer third at $62.58 billion of FY2025 revenue inside a five-company band that runs from Johnson & Johnson's Innovative Medicine at $60.40 billion to Eli Lilly's $65.18 billion, with Merck & Co. at $65.01 billion and AbbVie at $61.16 billion in between - scale-equal to its nearest peers rather than ahead of them. The same piece attributes the top slot to Lilly's tirzepatide franchise, which it puts at $36.5 billion combined and says passed Keytruda as the world's best-selling drug; Pfizer's 10-K names no comparable single franchise, discloses no market-share position for any product, and concedes in Item 1A that 'some of our competitors may have competitive, technical or other advantages over us' and that it faces 'an increasing number of potential competitors worldwide, including from China, that have expanded R&D capabilities.'

来源：sec.gov

The filing frames a 'highly competitive' market with 'frequent introduction of new or improved solutions' and a GPU cost base set by a single supplier (NVIDIA) — a renter of compute competing on efficiency has little list-price control.

来源：sec.gov

The filing's competitive factors lead with platform completeness, software and interoperability — ease of integration, not price, is stated first, which is where pricing power lives when it exists.

来源：sec.gov

Price is the lever the filing shows moving against it. CMS selected Eliquis - which the 10-K says 'accounted for 13% of Total revenues in 2025' - for the Medicare Drug Price Negotiation Program, and 'its government-set Maximum Fair Price became effective January 1, 2026', with Ibrance and Xtandi following in 2027 and Xeljanz in 2028. In September 2025 Pfizer 'voluntarily agreed' with the U.S. administration to make certain U.S. prices 'more comparable to those in other developed countries' and to sell through the TrumpRx.gov platform 'at significant discounts to current retail prices'. Gross-to-net product revenue deductions rose to $36,374 million in 2025 from $30,048 million in 2023 while Total revenues fell to $62,579 million, and the IRA Medicare Part D Redesign alone 'negatively impacted our 2025 revenues by approximately $1 billion'. Lower U.S. net price is named as a drag on Vyndaqel, Ibrance, Xeljanz, Nurtec ODT and Lorbrena; every 2025 growth line the filing explains is attributed to demand, patient share or launch uptake, none to price. Cost of sales at 25.7% of revenues shows the manufactured margin is intact - what is not intact is the ability to set the price.

来源：sec.gov

Layer-8 neocloud — a purpose-built AI compute provider reselling NVIDIA silicon at scale.

Layer-4 connectivity silicon inside AI servers, between accelerators, storage and NICs.

Demand side of the AI chain, not a supplier into it. The 10-K lists 'Scale AI across our business' as one of four 2026 key priorities and describes 'expanding automation, data-driven decision making, and enterprise AI solutions', crediting 'enhanced digital enablement, including automation and AI' for part of the savings in its cost-realignment and R&D-simplification programs. It describes no AI model, tool or platform that Pfizer sells.

• Nebius AI cloud (GPU compute + managed AI/ML platform) 挑战者 · 中等 来源：sec.gov
• Toloka / Avride / TripleTen (non-cloud segments) 未知 · 低 来源：sec.gov

• Aries PCIe/CXL Smart DSP Retimers and Smart Cable Modules 前三 · 中等 来源：sec.gov
• COSMOS software suite 未知 · 深 来源：sec.gov

• Comirnaty 未知 · 深 来源：sec.gov
• Eliquis 未知 · 低 来源：sec.gov
• Ibrance 未知 · 低 来源：sec.gov
• Padcev 未知 · 中等 来源：sec.gov
• Prevnar family 未知 · 中等 来源：sec.gov
• Vyndaqel family 未知 · 低 来源：sec.gov

编辑先验，未经回测。

查看它究竟如何投票 →

编辑先验，未经回测。

查看它究竟如何投票 →

编辑先验，未经回测。

查看它究竟如何投票 →